Mar 24
In February 2025 the FDA declared the semaglutide shortage officially resolved. Within 60 days, hundreds of 503A compounding pharmacies were told to wind down their GLP-1 programs. Within 90 days, 503B outsourcing facilities face the same directive.
Companies that had built entire revenue streams around the shortage exemption have almost no runway to adapt.
That enforcement decision was not a surprise to anyone who had been watching the regulatory cycle. It was a surprise to almost everyone who had not.
This is the GLP-1 supply chain story that is not being told loudly enough - not the headline numbers about Novo Nordisk and Eli Lilly, but the cascading operational consequences reshaping CDMO capacity, API sourcing, and manufacturing strategy across the entire biopharma sector in 2026.
If you are leading a growth-stage biopharma company right now and you have not stress-tested your supply chain against the GLP-1 ripple effect, are you operating with a gap in your risk model?
The Scale of the Disruption
The numbers establish the context. Novo Nordisk's semaglutide franchise - Ozempic and Wegovy - generated USD 26.6 billion in revenue in 2024, with Wegovy alone growing 86% year over year. Eli Lilly's tirzepatide products - Mounjaro and Zepbound - generated over USD 13.9 billion in 2024, with Zepbound capturing approximately 40% of the obesity market within its first year of launch.
The combined demand surge for GLP-1 active pharmaceutical ingredients has been unprecedented in the modern pharmaceutical industry. Novo Nordisk invested USD 6.1 billion in manufacturing capacity expansion in 2024 alone - including the USD 16.5 billion acquisition of Catalent, one of the largest CDMO transactions in industry history, specifically to secure fill-finish capacity for its GLP-1 programs.
When one company acquires one of the largest CDMOs in the world to secure its own supply chain, the consequences for every other company competing for capacity at that CDMO are immediate and material.
What This Means for Your CDMO Strategy
The CDMO market in 2026 looks materially different from 2022. Here is exactly what has changed.
Lead times at tier-one biologics CDMOs have extended by 30–50% since 2023, with cell and gene therapy manufacturing facilities reporting extensions of 50–100% as GLP-1 program demand has absorbed disproportionate capacity. What was a 12-month timeline from CDMO selection to commercial batch production is now running 18 to 24 months at most tier-one facilities. Lonza, Samsung Biologics, and WuXi Biologics are all operating at elevated utilization rates driven in part by GLP-1 program demand.
Minimum volume commitments have increased significantly. CDMOs are prioritizing clients who can fill capacity blocks consistently and predictably. Smaller biopharma companies with variable demand profiles are being quoted unfavorable terms or pushed down the queue entirely.
Pricing has reset upward. Fill-finish capacity that was available at market rates 18 months ago is now being quoted at premiums of 20–40% in some therapeutic categories. Companies that did not lock in multi-year agreements before the GLP-1 surge are now negotiating from a position of weakness.
Regulatory scrutiny on CDMO quality has intensified. The FDA issued 483 observations related to supply chain and manufacturing quality to 67 biopharma companies in 2025. The concentration of manufacturing activity at fewer, larger facilities creates systemic quality risk - a single FDA enforcement action at a major CDMO can simultaneously disrupt multiple client programs.
The Three CDMO Mistakes I See Most Often
Across 35+ years of building biopharma supply chains, I have seen the same CDMO mistakes made repeatedly - by well-funded, sophisticated companies that simply did not have enough operator-level supply chain experience at the leadership table.
Mistake 1: Starting CDMO conversations too late.
Most growth-stage biopharma companies begin serious CDMO conversations 12 months before they need commercial capacity. In the current market, that timeline needs to be 24 months minimum - and closer to 30 months for novel modality programs requiring specialized containment or cryogenic infrastructure.
The companies that are winning CDMO relationships right now began those conversations in 2023 and 2024. The companies starting them today are negotiating for slots that will be available in 2028.
Mistake 2: Single-source dependency.
Many growth-stage companies identify one CDMO, run a qualification process, and build their entire supply plan around a single manufacturing relationship. This is operationally efficient in a slack market. In the current market it is an existential risk.
Every commercial-stage supply chain needs a qualified secondary manufacturer - even if that secondary source is never activated. The qualification process alone takes 12–18 months. Starting it after your primary CDMO has a problem is too late.
Mistake 3: Treating CDMO negotiation as a procurement exercise.
CDMO relationships are strategic partnerships - not vendor contracts. The companies that get the best capacity, the best pricing, and the best quality attention are the ones whose leadership teams have built personal relationships with CDMO executive teams over years.
Sending a procurement team to negotiate with a CDMO you have never worked with before, in the most capacity-constrained market in a decade, is not a viable strategy.
The API Sourcing Problem Nobody Is Talking About
The CDMO capacity crunch is the visible part of the GLP-1 supply chain crisis. The API sourcing problem is less visible and potentially more consequential for growth-stage companies.
Semaglutide and tirzepatide API production is concentrated in a small number of facilities - primarily in China and India. The surge in GLP-1 demand has absorbed significant synthetic peptide API capacity at facilities that also supply non-GLP-1 programs.
Companies sourcing APIs for peptide-based therapeutics, novel formulations, or biosimilar programs from these same supplier networks are experiencing allocation constraints that were not present 18 months ago.
The strategic response requires mapping your API supply chain at least two tiers deep - identifying not just your direct API supplier but their key raw material and intermediate suppliers. Single-source dependencies at tier two of your supply chain are as dangerous as single-source dependencies at tier one, and far less visible.
The FDA Compounding Enforcement Lesson
The FDA's 2025 enforcement actions against GLP-1 compounders carry a broader lesson for every biopharma CEO - not just those in the compounding space.
Section 503A and 503B compounding exemptions exist within a regulatory framework that the FDA reinterprets as market conditions change. The agency's decision to declare the semaglutide shortage resolved and initiate enforcement against compounders was legally defensible, operationally predictable, and financially catastrophic for companies that had not built regulatory flexibility into their business model.
This pattern recurs across drug delivery innovation, biosimilar approval pathways, and specialty generics. The regulatory environment consistently rewards companies that plan for multiple scenarios, not just the most favorable one.
The practical implication: for any program touching novel drug delivery, compounding, or biosimilar pathways, build a regulatory risk matrix that explicitly accounts for FDA enforcement scenarios that change your commercial assumptions. The cost of that planning exercise is trivial compared to the cost of being unprepared when the regulatory environment shifts.
What to Do Right Now - A Five-Point Supply Chain Audit
If you have not conducted a formal supply chain stress test in the past 12 months, do it now. Here is the framework:
1. CDMO capacity audit.
Map your current CDMO relationships against your 24-month production requirements. Identify capacity gaps and initiate secondary CDMO qualification conversations immediately.
2. API sourcing depth review.
Map your API supply chain two tiers deep. Identify single-source dependencies at both tier one and tier two. Build secondary sourcing relationships before you need them.
3. Contract terms review.
Review your existing CDMO and API supplier contracts for force majeure provisions, allocation clauses, and minimum volume commitments. Identify contracts that leave you exposed in a supply disruption.
4. Regulatory scenario planning.
For every program touching a regulatory pathway that has been subject to recent FDA guidance or enforcement activity - compounding, biosimilar interchangeability, novel delivery mechanisms - build explicit contingency plans for adverse regulatory scenarios.
5. Integration diligence check.
If you are preparing for a transaction, as acquirer or target, treat supply chain as a tier-one diligence workstream, not a secondary concern. Supply chain issues are consistently among the most material post-close surprises in biopharma M&A. The FDA 483 observation history of your target's manufacturing partners is as important as its clinical data package.
The GLP-1 supply chain crisis is not a Novo Nordisk problem or an Eli Lilly problem. It is a structural market disruption that is reshaping CDMO capacity, API sourcing, and regulatory enforcement dynamics for every biopharma company operating in 2026.
The companies that will navigate it successfully are the ones treating supply chain as a CEO-level strategic priority, not delegating it to a procurement function and hoping for the best.
At Katogen, we help biopharma leadership teams build supply chains that are scalable, resilient, and designed to withstand the kind of market disruptions that define this industry. Every engagement is led directly by our founder, Doug Drysdale a 35-year operator with 18 years of CEO experience and USD 4B+ raised across the full biopharma value chain.
Doug Drysdale is the founder of Katogen, a biopharma advisory and strategy firm. With 35+ years of operator experience including CEO roles at Alvogen and Cybin, 17 completed acquisitions, and USD 4B+ raised, Katogen helps growth-stage and mid-sized biopharma companies navigate complex strategic challenges. Learn more at katogen.com.
